Categories
Loading...
Categories
Neuland Laboratories reported Q2FY25 income of ₹315.2 crore, a 25.1% decline year-over-year, with EBITDA at ₹65.7 crore, down 53.2%. The company acknowledged subpar performance but remains optimistic about long-term growth driven by new customer acquisitions and facility expansions. The management anticipates a favorable environment for growth in FY26 and beyond, with key revenue contributions from specialty commercial molecules. An earnings call will provide further insights into the company’s performance.